BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology names. BTIG is now modeling about $1.5B in U.S. Farapulse revenue in 2025, up from $1B in its prior projections, which had “conservatively” used its Q4 estimate as a runrate, the analyst tells investors in a research note, adding that BTIG believes that this new forecast “remains achievable”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific price target raised to $110 from $100 at Truist
- FDA says Boston Scientific Accolade pacemakers may need early replacement
- Boston Scientific price target raised to $110 from $100 at TD Cowen
- Boston Scientific price target raised to $107 from $98 at Citi